1. Patients with psoriasis receiving biologic therapies showed a lower risk of developing cardiovascular disease compared to those receiving oral anti-psoriatic medications.
2. The study involved over 25,000 patients across multiple health care systems worldwide, spanning from 2014-2025.
3. Biologic therapies targeted tumor necrosis factor (TNF)-alpha, interleukin (IL)-17, IL-23, and IL-12/23, showing consistent lower cardiovascular risk. 
4. Hazard ratios consistently favored biologic therapy, with a 38% relative risk reduction in cardiovascular disease incidence among biologics group. 
5. The study noted limitations due to its observational design, acknowledging that causality cannot be established.

Source: PLOS Medicine